据路透社消息,近日,德国默克表示,该公司与Threshold制药联合开发的癌症试验药物Evofosfamide用于晚期胰腺癌获得了美国FDA快速通道审评资格。德国默克在2012年已经从Threshold手中许可获得Evofosfamide,这款药物之前也称做TH-302。该药物能够攻击缺乏氧供应的人体组织,而缺乏氧供应是众多肿瘤的一个典型特征,因为肿瘤细胞通常在增长时不连接到其周围的 According to Reuters, Merck recently said that the company and Threshold Pharmaceutical jointly developed the cancer test drug Evofosfamide for advanced pancreatic cancer access to the US FDA fast track review eligibility. Merck Germany has licensed Evofosfamide from Threshold in 2012, the drug also formerly known as TH-302. The drug is able to attack human tissues lacking oxygen supply, and the lack of oxygen supply is a classic feature of many tumors because tumor cells are usually not growing around them